Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VQW-765

Other · developed by Vanda Pharmaceuticals

Phase 3 Most advanced trial
VNDA Developer
1 Registered trials

What is VQW-765?

VQW-765 is an investigational drug studied in Social Anxiety Disorder (SAD).

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
Vanda Pharmaceuticals (VNDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07221578 Phase 3 Social Anxiety Disorder (SAD) Active not recruiting VNDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Social Anxiety Disorder (SAD)

More from Vanda Pharmaceuticals

Iloperidone FDA approved Milsaperidone FDA approved Ponesimod FDA approved Tasimelteon FDA approved Tradipitant FDA approved Trichostatin A Phase 2 VCA-894A Phase 1/2 VSJ-110 Phase 2

Follow VNDA, the company behind VQW-765

See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VNDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.